On February 1, 2021 Exact Sciences Corp. (Nasdaq: EXAS) reported that the company plans to release its fourth quarter 2020 financial results after the close of the U.S. financial markets on February 16, 2021 (Press release, Exact Sciences, FEB 1, 2021, View Source [SID1234574457]). Following the release, company management will host a webcast and conference call at 5 p.m. EST to discuss financial results and business progress.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Exact Sciences Corporation Logo (PRNewsfoto/EXACT SCIENCES CORP)

Fourth quarter 2020 webcast & conference call details

Date: Tuesday, February 16, 2021

Time: 5 p.m. EST, 4 p.m. CST

Webcast: The live webcast can be accessed at www.exactsciences.com

Access code for both domestic and international callers: 2892148

An archive of the webcast will be available at www.exactsciences.com. A replay of the conference call will be available by calling 800-585-8367 domestically or 416-621-4642 internationally. The access code for the replay of the call is 2892148. The webcast, conference call and replay are open to all interested parties.

On February 1, 2021 Therapeutic Solutions International, Inc., (OTC Markets: TSOI), reported new data demonstrating regression of an animal model of glioma using exosomes isolated from the Company’s cellular immunotherapy product StemVacs (Press release, Therapeutics Solutions International, FEB 1, 2021, View Source [SID1234574474]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Exosomes are cell derived nanoparticles which have been demonstrated to transmit biological information between cells. Dr. Thomas Ichim, Board Member of the Company, published 16 years ago that exosomes from cancer are capable of suppressing immunity1. Today the Company reported opposite findings: in some situations, immune cell exosomes can suppress cancer.

"The current findings demonstrate that StemVacs derived exosomes can directly stimulate natural killer cells, which in turn, suppress glioma growth" said Dr. James Veltmeyer, Chief Medical Officer of the Company and co-inventor of the patent. "Exosomes in some cases possess advantages to administration of cells in that they are more stable than cells and are capable of superior biodistribution due to their small size."

"As a clinical stage cancer immunotherapy company, experimental validation of our intellectual property is extremely important for accomplishing our goals of entering into licensing and/or co-development relationships with Large Pharma" stated Famela Ramos Vice President of Business Development. "The fact that companies such as Fate Therapeutics and Nantkwest are attracting valuations in the billions of dollars, supports our belief that the field of natural killer therapeutics is highly perceived by the industry".

"We are in the process of developing responses to our last interaction with the FDA regarding StemVacs cell therapy" said Timothy Dixon, President and CEO of the Company. "By leveraging our scientific colleagues and finding that StemVacs exosomes are effective in glioma, we are evaluating the possibility of applying for another Investigational New Drug application using exosomes."

On January 31, 2021, Adhera Therapeutics, Inc. (the "Company") reported that issued to an existing investor in and lender to the Company a 10% original issue discounted Senior Secured Convertible Promissory Note for a purchase price of $52,778 (the "Note") (Filing, 8-K, Adhera Therapeutics, JAN 31, 2021, View Source [SID1234574793]). Additionally, the Company issued to the investor 753,968 warrants to purchase the Company’s common stock at an exercise price of $0.08 per share (the "Warrant").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pursuant to the Note, the Company promises to pay the principal sum of the Note to the noteholder on the date that is the six- month anniversary of the original issue date, or such earlier date as the Note is required or permitted to be repaid as provided thereunder, and to pay interest to the noteholder on the aggregate unconverted and then outstanding principal amount of the Note in accordance with the provisions thereof. Interest shall accrue on the aggregate unconverted and then outstanding principal amount of the Note at the rate of 10% per annum, calculated based on a 360-day year and shall accrue daily commencing on the original issue date until payment in full of the outstanding principal (or conversion to the extent applicable), together with all accrued and unpaid interest, liquidated damages and other amounts which may become due thereunder, has been made.

The Note is convertible, in whole or in part, at any time, and from time to time, into shares of the common stock of the Company at the option of the noteholder at a conversion price of $0.07 (as adjusted for stock splits, stock combinations and similar events); provided, that if an event of default has occurred under the Note, then the conversion price shall be 70% of the then conversion price. The conversion price shall also be adjusted upon subsequent equity sales by the Company. The obligations of the Company under the Note are secured by a senior lien and security interest in all assets of the Company.

The foregoing summaries of the material terms of the form of Note and the form of Warrant are not complete and are qualified in their entirety by reference to the full text thereof, copies of which are filed herewith as Exhibits 4.1 and 4.2, respectively, and incorporated by reference herein.

On January 31, 2021 MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), reported the closing of the previously announced private placement transaction under a Securities Purchase Agreement, dated January 11, 2021, pursuant to which MediciNova issued US$20 million in shares of its common stock to 3D Opportunity Master Fund, a fund managed by 3D Investment Partners Pte. Ltd. ("3D") (Press release, MediciNova, JAN 31, 2021, View Source [SID1234574441]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MediciNova intends to use the proceeds received from the private placement primarily for the following three programs:

1) To initiate a new clinical trial of MN-166 (ibudilast) for glioblastoma, which could be a pivotal trial.

2) To develop an intravenous formulation of MN-166 (ibudilast), which is ideal for amyotrophic lateral sclerosis (ALS) patients who have difficulty with swallowing.

3) To initiate a Phase 2 clinical trial of MN-001 (tipelukast) in nonalcoholic steatohepatitis (NASH).

On January 31, 2021, Arcus Biosciences, Inc. ("Arcus") and Gilead Sciences, Inc. ("Gilead") reported that it entered into an Amended and Restated Common Stock Purchase Agreement (the "A&R Purchase Agreement"), which amends and restates in its entirety the Common Stock Purchase Agreement entered into between Arcus and Gilead on May 27, 2020 (the "Original Purchase Agreement") (Filing, 8-K, Arcus Biosciences, JAN 31, 2021, View Source [SID1234574450]). Pursuant to the A&R Purchase Agreement, Gilead will purchase from Arcus 5,650,000 shares of Arcus common stock at a purchase price of $39.00 per share, subject to customary closing conditions. All other terms of the Original Purchase Agreement, including Gilead’s option to purchase additional shares from Arcus, up to a maximum of 35% of Arcus’s then-outstanding common stock, from time to time until July 13, 2025, remain unchanged.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The foregoing is only a brief description of the material terms of the A&R Purchase Agreement and does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to the agreement, which will be filed as an exhibit to Arcus’s Annual Report on Form 10-K for the year ended December 31, 2020.